Wall Street PR

Alan Masterson

Alkermes Plc (NASDAQ:ALKS): What Next?

Boston, MA 04/08/2014 (wallstreetpr) – Alkermes Plc (NASDAQ:ALKS), a $5.93 billion drug company, announced that its experimental drug intended for treatment of schizophrenia, met late-stage study

VSE Corporation (NASDAQ:VSEC) Can Still Be Traced

Boston, MA 04/04/2014 (wallstreetpr) – VSE Corporation (NASDAQ:VSEC) is a provider of centralized management for other businesses. The company runs owned and operated centers. Doing business

Alkermes Plc (NASDAQ:ALKS): What Next?

Boston, MA 04/08/2014 (wallstreetpr) – Alkermes Plc (NASDAQ:ALKS), a $5.93 billion drug company, announced that its experimental drug intended for treatment of schizophrenia, met late-stage study

VSE Corporation (NASDAQ:VSEC) Can Still Be Traced

Boston, MA 04/04/2014 (wallstreetpr) – VSE Corporation (NASDAQ:VSEC) is a provider of centralized management for other businesses. The company runs owned and operated centers. Doing business